A clinical, evidence-graded monograph for every peptide.
The Peptide Encyclopedia is our A-Z reference of individual peptide monographs. Each entry covers what a peptide is, how it works, the strength of the human and preclinical evidence behind it (graded A-D), the doses and routes reported in the literature, its documented risks, and its current FDA and anti-doping status — every claim tied to a real, verifiable source. It is the reference spine of the site, written for readers who want the clinical record rather than the hype.
A clinical monograph on Cardiogen (AEDR; H-Ala-Glu-Asp-Arg-OH), the cardiac-targeted Khavinson bioregulator tetrapeptide. Coherent in-vitro mechanism, zero human trials, and an unapproved 2026 legal status.
A clinical monograph on larazotide acetate (AT-1001) — the gut tight-junction regulator developed for celiac disease. Real Phase 2 symptom data, a failed Phase 3, and an unapproved 2026 legal status.
Peptide EncyclopediaA clinical monograph on KPV — the anti-inflammatory tripeptide fragment of alpha-MSH. Deep rodent and cell-culture data for gut and skin inflammation, zero human trials, and an unsettled 2026 legal status.
Peptide EncyclopediaA clinical monograph on Kisspeptin-10 (KP-10), the KISS1R/GPR54 agonist that drives the reproductive axis. Robust human physiology data, no Grade-A outcome RCT, and a 2026 legal status that is not-approved, non-compoundable and banned in sport.
Peptide EncyclopediaA clinical monograph on ipamorelin — the selective growth-hormone secretagogue famous for the CJC-1295 stack. One human PD study, one failed RCT, and an unsettled 2026 legal status.
Peptide EncyclopediaA clinical monograph on the tesamorelin + ipamorelin stack — a GHRH-analog plus ghrelin-receptor agonist combination marketed for body composition. Sound mechanism, Grade-A component data, but zero RCTs of the combination itself.
Peptide EncyclopediaA clinical monograph on insulin — the prototype FDA-approved therapeutic peptide. Grade-A human evidence in diabetes, a tyrosine-kinase mechanism, and a stark warning on lethal non-medical 'anabolic' misuse.
Peptide EncyclopediaA clinical monograph on IGF-1 LR3 (Long R3 IGF-1) — the IGFBP-evading, long-acting IGF-1 receptor agonist sold as a lab reagent. Real animal anabolic signal, zero human trials, and serious hypoglycemia and cancer-promotion concerns.
Peptide EncyclopediaA clinical monograph on des(1-3)IGF-I — the truncated, IGFBP-evading IGF-1 analogue marketed for localized muscle growth. Potent in rodents, unproven in humans, and WADA-banned at all times.
Peptide EncyclopediaA clinical monograph on humanin — the first mitochondrial-derived peptide. Deep preclinical cytoprotection data, intriguing human biomarker correlations, zero interventional human trials, and a real tumor-promotion caveat.
Peptide EncyclopediaA clinical monograph on HGH Fragment 176-191 — the C-terminal 'lipolytic tail' of growth hormone sold as a fat-loss peptide. No human RCTs, an antilipogenic animal mechanism, and a closely related analogue (AOD-9604) that failed its pivotal obesity trial.
Peptide EncyclopediaA clinical monograph on the injectable FSH and LH analogs of reproductive medicine — Grade A, FDA-approved biologics validated by large RCTs and a Cochrane meta-analysis of ~9,600 couples, with OHSS and multiple gestation as the headline risks.
Peptide EncyclopediaA clinical monograph on human chorionic gonadotropin (hCG) — the FDA-approved LH-mimetic hormone used to trigger ovulation and preserve intratesticular testosterone, with the 'hCG diet' debunked and illegal.
Peptide EncyclopediaA clinical monograph on hexarelin (examorelin) — one of the most potent growth-hormone-releasing peptides. Real human GH-provocation and acute cardiac data (Grade B), preclinical cardioprotection claims (Grade C), and a 2026 status that is unapproved and banned in sport.
Peptide EncyclopediaA clinical monograph on gonadorelin — synthetic native GnRH used as an HPG-axis diagnostic and as pulsatile pump therapy. Real human efficacy in narrow indications, but the popular TRT-adjunct use is essentially unstudied.
Peptide EncyclopediaA clinical monograph on glutathione (GSH) — the body's master antioxidant tripeptide marketed for skin lightening, liver support and 'detox.' Real human RCTs for raising body stores, mixed cosmetic data, and dangerous unapproved IV use.
Peptide EncyclopediaA clinical monograph on glycyl-L-glutamine (Gly-Gln) — the stable glutamine-carrier dipeptide of parenteral nutrition that is also the endogenous β-endorphin-(30–31) neuropeptide. Real human-trial evidence for IV glutamine delivery; cardiometabolic claims are preclinical only.
Peptide EncyclopediaA clinical monograph on glucagon — the 29-amino-acid pancreatic counter-regulatory hormone. FDA-approved since 1960 for severe-hypoglycemia rescue, graded A on decades of human RCTs, and now the glucagon-receptor arm of next-generation metabolic agonists.
Peptide EncyclopediaA clinical monograph on SS-20 — the Szeto-Schiller mitochondria-targeting tetrapeptide that protects mitochondria without antioxidant chemistry. Deep preclinical data, no human trials, and unapproved research-only status in 2026.
Peptide EncyclopediaA clinical monograph on teduglutide — the GLP-2 receptor agonist FDA-approved for short bowel syndrome with intestinal failure. Grade A RCT evidence for SBS-IF, a mandated neoplasia-surveillance burden, and unproven 'leaky-gut' hype.
A peptide monograph is a single, structured reference page for one peptide. On PeptideVox each monograph covers identity and chemistry, mechanism of action, the indication-by-indication evidence (each graded A-D), reported dosing and routes from the literature, safety and contraindications, and current legal and anti-doping status. Every efficacy claim carries an evidence grade and an inline citation to a real study, regulatory document, or trial registry so you can check the source yourself. The format is informational and editorial — it is not medical advice.
PeptideVox grades every efficacy claim on an A-D scale. Grade A means human randomized controlled trials or meta-analyses support the claim; grade B means lower-tier human evidence such as cohort or open-label studies; grade C means preclinical only (animal or in-vitro) with no qualifying human efficacy data; and grade D means anecdotal, mechanistic-only or marketing claims with no controlled evidence. Grading is deliberately conservative — preclinical promise never earns an A or B, and the grade always reflects the human-evidence level when human and animal data conflict.
No. The encyclopedia is strictly informational and editorial. It does not recommend vendors, link to sellers of unapproved peptides, or tell you how to source or self-administer anything. Dosing figures are reported only as they appear in the published literature and clinical or anecdotal use, for completeness — never as a protocol to follow. Many peptides covered here are not FDA-approved, are sold as "research chemicals not for human use," and may be prohibited in sport. Always consult a licensed clinician before any health decision.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.
